Alan Schatzberg
Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences at Stanford University; Director of the Stanford Mood Disorders Center
Data updated
Research Footprint
Alan Schatzberg appears in 7 tracked papers (2017–2026), most studied alongside Ketamine, Placebo and Esketamine, across Depressive Disorders, Anxiety Disorders and Major Depressive Disorder (MDD).
Most-cited paper: A consensus statement on the use of ketamine in the treatment of mood disorders (571 citations).
Frequent co-authors: Boris Heifets, Gerard Sanacora and Charles Debattista.
Background & Research
Alan F. Schatzberg, MD, is a psychiatrist and Stanford faculty member whose work has focused on the biology and treatment of depressive disorders. He has held leadership roles at Stanford for decades, including chairing Psychiatry and Behavioral Sciences and directing the Stanford Mood Disorders Center. His research has been especially influential in psychopharmacology and in ketamine’s use for mood disorders.
Key Impact
He is a major figure in mood-disorder research and helped shape the modern clinical discussion of ketamine as a rapid-acting antidepressant and its opioid-mediated effects.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Alan Schatzberg is associated with.
Stanford University
academicAt the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).
View stakeholder →Mclean Hospital
Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.
View stakeholder →